Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS
NCT05580458Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2023
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2023; status: recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05580458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580458.